Colgate-Palmolive Company (CL) Stock: Price, Forecast & Analyst Target
Colgate-Palmolive Company (CL) — MoonshotScore 88/100 (Exceptional band), calculated Oct 5, 2026. Price $84.26 (-0.32%), as of the Oct 2, 2026 trading session; market cap $67.4B. Expected results Oct 30, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 49.20× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Oct 30, 2026
Colgate-Palmolive Company · CL · NYSE · Consumer Defensive · Household & Personal Products
Research dated 2026-09-12: Colgate-Palmolive sells repeat-purchase oral, personal and home-care products alongside Hill's pet nutrition through retail, dental and veterinary channels. The case hinges on whether steady sales expansion can absorb higher input costs, tariffs and planned brand spending while restoring the conversion of revenue into operating profit.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Colgate-Palmolive Company (CL)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a strong balance sheet, but a full valuation. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Rising.
Price relative to book value is the main valuation drag relative to sector peers.
- quarterly revenue $5.36B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- expected results Oct 30, 2026
Holding back: a rich price
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 87 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional | |
| 88 | Exceptional |
The score was 88 in the stored Oct 4, 2026 snapshot and remains 88 in the current publication computed Oct 5, 2026 (0). This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $84.26 | |
| Change on the day | -0.32% | |
| 52-week range | $74.55–$99.33 | |
| Market capitalisation | $67.4B | |
| Price / earnings (trailing) | 33.12 | |
| Shares traded on the day | 6.60M | |
| Beta (volatility vs the S&P 500) | 0.32 | |
| Dividends per share (last 12 months) | $2.10 | |
| Dividend yield (last 12 months) | 2.49% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We will also deliver against our strategic growth and productivity program as we build the right organizational structure to deliver against our 2030 strategy.
Noel Wallace · Statement from
We've increased our gross margin guidance to roughly flat for the year, but we do have to keep in mind that we do expect the higher raw materials and tariffs will be higher in the second half of the year than they were in the second quarter.
Stanley Sutula · Statement from
Chronological order, not a duration scale. Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsCouncil Score · weighted blend of 2 available disciplines
Council score for Colgate-Palmolive Company (CL): Bullish Lean
74/100 · ASome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CL film — every key number, told as a short cinematic story
~2 min · open the film
What is Colgate-Palmolive Company (CL), and what does it report?
Short answer · as of
Colgate-Palmolive is much more than a toothpaste and soap company.
Research dated 2026-09-12.
Colgate-Palmolive is much more than a toothpaste and soap company. Its main business spans oral care, personal care and household products, while Hill's sells everyday and therapeutic nutrition for dogs and cats; professional oral-health products add dentists to a distribution network otherwise built around retailers, wholesalers, veterinary clinics and online platforms.
Reported revenue separates Oral, Personal and Home Care from Pet Nutrition. The consumer-care group remains the larger contributor, but the pet business gives the company exposure to animal health needs and veterinary distribution rather than only household shopping patterns.
What do the latest results show for Colgate-Palmolive Company (CL)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $5.36B.
Research dated 2026-09-12.
Sales advanced again in the latest period, extending an upward annual trajectory. Gross profit also increased, but operating profit pulled back alongside higher selling, general and administrative expense, so the latest top-line gain did not fully reach operating earnings. Net income improved from the preceding period after the unusual loss recorded around the annual close.
Reported earnings have repeatedly exceeded expectations, while revenue has beaten estimates in nearly every recent release. Management attributes the prospective improvement path to new-product execution, closing promotional gaps, greater advertising support and a broader productivity program; those are stated priorities, not yet proof that profit conversion has recovered.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $5.36B Jun 30, 2026
- Latest quarter · SG&A
- $2.13B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $1.02B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $5.36B | Not available | $2.13B | $1.02B |
| Mar 31, 2026 | $5.32B | Not available | $2.07B | $1.16B |
| Dec 31, 2025 | $5.23B | Not available | $2.07B | $1.08B |
| Sep 30, 2025 | $5.13B | Not available | $1.99B | $1.10B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.36B Jul 31, 2026
- Latest report · revenue estimate
- $5.36B Jul 31, 2026
- Latest report · revenue vs estimate
- In line Jul 31, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 31, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 31, 2026 | $5.36B | $5.36B | $0.9900 | $0.9470 |
| May 1, 2026 | $5.32B | $5.22B | $0.9700 | $0.9430 |
| Jan 30, 2026 | $5.23B | $5.12B | $0.9500 | $0.9120 |
| Oct 31, 2025 | $5.13B | $5.13B | $0.9100 | $0.8890 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $5.36B | $693M | $0.86 (diluted) |
| Q1 FY2026 | $5.32B | $646M | $0.80 (diluted) |
| Q4 FY2025 | $5.23B | -$37M | -$0.05 (diluted) |
| Q3 FY2025 | $5.13B | $735M | $0.91 (diluted) |
What are the financial strengths and risks for Colgate-Palmolive Company (CL)?
Short answer
Cash and short-term investments were $1.37B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $995.00M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has exceeded capital spending throughout the reported series, leaving meaningful internally generated funds after investment in the business. Cash has remained within a relatively narrow range and finished only modestly below its opening level, which points to stability rather than a persistent operating drain.
Debt materially exceeds cash and short-term investments. Near-term liquidity appears adequate but not abundant, making sustained cash generation more important than the cash balance alone; strong distress and financial-quality screens provide a counterweight, but they do not remove refinancing or execution risk.
Higher raw-material costs and tariffs could pressure gross profit just as management increases advertising. That combination would hurt if brand support fails to produce enough sales or pricing benefit, especially because annual revenue growth has recently coexisted with uneven net income.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $995.00M Jun 30, 2026
- Previous quarter · operating cash flow
- $747.00M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $995.00M | −$128.00M |
| Mar 31, 2026 | $747.00M | −$138.00M |
| Dec 31, 2025 | $1.45B | −$177.00M |
| Sep 30, 2025 | $1.26B | −$155.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Colgate-Palmolive Company (CL)?
Short answer · as of
The next earnings report is expected on Oct 30, 2026.
Research dated 2026-09-12.
The next release should be judged on the link between sales, gross profit and operating profit rather than revenue alone. Management expects greater raw-material and tariff pressure later in the year while stepping up advertising and addressing promotion gaps and new-product execution. Continued sales progress with stable gross profitability and firmer operating profit would support that plan; weakening gross profit as spending rises would challenge it.
Cost actions also deserve attention. Recent company reporting flagged costs associated with exit or disposal activities, while management tied its longer-term strategy to productivity and organizational structure. The useful test is whether those actions improve profit conversion rather than merely shift expenses.
Analyst forecasts assume revenue and earnings continue rising across the forecast horizon. Upcoming results therefore need to sustain the recent pattern of expectation beats while showing that the operating engine, not only adjusted earnings, is strengthening.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We will also deliver against our strategic growth and productivity program as we build the right organizational structure to deliver against our 2030 strategy.
Noel Wallace ·
We've increased our gross margin guidance to roughly flat for the year, but we do have to keep in mind that we do expect the higher raw materials and tariffs will be higher in the second half of the year than they were in the second quarter.
Stanley Sutula ·
And as I also mentioned, we're going to step up our spending in the back half of this year, not competitive in some of the categories in terms of advertising support.
Noel Wallace ·
And that's what we're going to be laser-focused on, getting the execution of our new products, getting the promotion gaps that we have addressed but do it thoughtfully and making sure that we have the investment in the back half of the P&L to generate sequential improvement as we move -- compare the second half versus the first half.
Noel Wallace ·
How does Colgate-Palmolive Company compare with its peers?
Short answer
Colgate-Palmolive Company's score ranks 1st of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Colgate-Palmolive combines mass-market household staples with a specialized pet-nutrition franchise. Hill's sells everyday food as well as therapeutic diets for health conditions through veterinary clinics, pet retailers and online channels, while the consumer-care portfolio reaches broad retail distribution and dental professionals.
That mix differs from a household-products business dependent solely on supermarket and pharmacy shelves. Pet Nutrition remains the smaller reported segment, yet its veterinary orientation, therapeutic products and dedicated veterinary leadership create a distinct customer and demand structure within the same company.
| Company | Price | Market value | Score |
|---|---|---|---|
| Colgate-Palmolive Company (CL) — this page | $84.26 | $67.4B | 88 |
| $84.75 Oct 2, 2026 | $47.1B | 75 5-pillar Oct 5, 2026 | |
| $101.06 Oct 2, 2026 | $44.8B | 74 5-pillar Oct 5, 2026 | |
| $17.20 Oct 2, 2026 | $33.0B | 70 5-pillar Oct 5, 2026 | |
| $58.19 Oct 2, 2026 | $74.3B | 65 5-pillar Oct 5, 2026 | |
| $59.03 Oct 2, 2026 | $36.2B | 63 5-pillar Oct 5, 2026 | |
| $59.70 Date unavailable | $129B | — Model unavailable | |
| $91.97 Date unavailable | $33.3B | — Model unavailable | |
| $94.36 Date unavailable | $31.3B | — Model unavailable | |
| $94.31 Date unavailable | $22.4B | — Model unavailable | |
| $144.91 Date unavailable | $344B | — Model unavailable | |
| $61.97 Date unavailable | $13.0B | — Model unavailable | |
| $80.41 Date unavailable | $9.72B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $79.00 – $109.00
- Consensus target
- $98.11
- Median target
- $100.00
Consensus record · Captured .
Measured against a quoted price of $84.26 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 54
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 4
- Other transactions
- 50
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 84.2% Period end Jun 30, 2026
- Previous quarter · ownership
- 83.5% Prior to period end Jun 30, 2026
- Reporting holders
- 2,079 Period end Jun 30, 2026
- Previous quarter · holders
- 2,020 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 69,915,472 |
| Vanguard Capital Management LLC | 52,246,333 |
| State Street Corp | 47,020,966 |
| Price T Rowe Associates INC /Md/ | 27,909,525 |
| Vanguard Portfolio Management LLC | 24,021,137 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Colgate-Palmolive Company (CL)?
What Investors Ask About Colgate-Palmolive Company (CL) — Consumer Defensive
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What makes Hill's Prescription Diet different from Colgate-Palmolive's household brands?
Hill's Prescription Diet consists of therapeutic foods designed to help manage health conditions in dogs and cats. Veterinary clinics form part of its distribution network, giving the franchise a professional animal-health channel that household cleaners and personal-care products do not share.
Is Colgate-Palmolive still mainly an oral, personal and home-care company?
Oral, Personal and Home Care remains the larger reported business. Hill's Pet Nutrition is nevertheless a substantial separate contributor with different products, customers and routes to market.
Why did Colgate-Palmolive's latest sales growth not produce higher operating profit?
Gross profit rose, but selling, general and administrative expense also climbed and operating profit declined. Management is planning heavier advertising support, making the conversion of brand spending into sales and profit an important test.
Can Colgate-Palmolive fund its brands while carrying more debt than cash?
Current cash generation has covered capital spending with ample room remaining, supporting continued business investment. Debt is still far larger than cash, and liquid-asset coverage is not generous, so that capacity depends on operating cash flow remaining durable.
What is the CL stock price today?
The last price recorded on this page for Colgate-Palmolive Company (CL) is $84.26, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CL price target?
The analyst consensus price target for Colgate-Palmolive Company (CL) is $98.11 (range $79.00 to $109.00, median $100.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
When are CL's next earnings?
The next earnings date listed on this page for Colgate-Palmolive Company (CL) is Oct 30, 2026. Companies sometimes move report dates, so the company's own announcement is the final word on timing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Noel Wallace (Jul 31, 2026): We will also deliver against our strategic growth and productivity program as we build the right organizational structure to deliver against our 2030 strategy. Stanley Sutula (Jul 31, 2026): We've increased our gross margin guidance to roughly flat for the year, but we do have to keep in mind that we do expect the higher raw materials and tariffs will be higher in the second half of the year than they were in the second quarter. Noel Wallace (Jul 31, 2026): And as I also mentioned, we're going to step up our spending in the back half of this year, not competitive in some of the categories in terms of advertising support. Noel Wallace (Jul 31, 2026): And that's what we're going to be laser-focused on, getting the execution of our new products, getting the promotion gaps that we have addressed but do it thoughtfully and making sure that we have the investment in the back half of the P&L to generate sequential improvement as we move -- compare the second half versus the first half. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | NEW York, NY | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "300 Park Avenue, New York City, NY, 10022-7499, US". |
FMP — 69 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $84.26 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T00:34:47.109Z. | |
px.change | Change on the day | -0.32% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $67.4B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:03.000Z. Captured from FMP at 2026-10-05T00:34:46.132Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.27 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $5.36B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $74.55–$99.33 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 33.12 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 6.60M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.32 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Noel R. Wallace | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 33,600 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $17.42B, net result $2.17B; FY2022 revenue $17.97B, net result $1.78B; FY2023 revenue $19.46B, net result $2.30B; FY2024 revenue $20.10B, net result $2.89B; FY2025 revenue $20.38B, net result $2.13B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Pet Nutrition $4.61B · Oral, Personal and Home Care $15.77B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 60.4% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $5.36B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $2.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $1.02B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $5.32B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $2.07B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $1.16B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $5.23B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $2.07B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $1.08B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $5.13B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $1.99B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $1.10B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-07-31.revenue_actual | Revenue · reported — report date 2026-07-31 | $5.36B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.revenue_estimated | Revenue · estimate — report date 2026-07-31 | $5.36B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_actual | EPS · reported — report date 2026-07-31 | $0.9900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-31.eps_estimated | EPS · estimate — report date 2026-07-31 | $0.9470 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-01.revenue_actual | Revenue · reported — report date 2026-05-01 | $5.32B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-01.revenue_estimated | Revenue · estimate — report date 2026-05-01 | $5.22B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-01.eps_actual | EPS · reported — report date 2026-05-01 | $0.9700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-01.eps_estimated | EPS · estimate — report date 2026-05-01 | $0.9430 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_actual | Revenue · reported — report date 2026-01-30 | $5.23B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.revenue_estimated | Revenue · estimate — report date 2026-01-30 | $5.12B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_actual | EPS · reported — report date 2026-01-30 | $0.9500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-30.eps_estimated | EPS · estimate — report date 2026-01-30 | $0.9120 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.revenue_actual | Revenue · reported — report date 2025-10-31 | $5.13B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.revenue_estimated | Revenue · estimate — report date 2025-10-31 | $5.13B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.eps_actual | EPS · reported — report date 2025-10-31 | $0.9100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-31.eps_estimated | EPS · estimate — report date 2025-10-31 | $0.8890 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.37B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $995.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $7.86B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 284.40× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $995.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $747.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$128.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$138.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $1.45B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$177.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $1.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$155.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $79.00 – $109.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $98.11 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $100.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 54 transactions · 0 purchases, 4 sales, 50 other transactions · 12 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 84.2% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 83.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 2,079 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 2,020 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 69,915,472 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Vanguard Capital Management LLC — shares in provider snapshot | 52,246,333 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | State Street Corp — shares in provider snapshot | 47,020,966 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Price T Rowe Associates INC /Md/ — shares in provider snapshot | 27,909,525 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 24,021,137 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Oct 30, 2026 | UNRECORDED | Stored earnings-calendar observation — Captured 2026-08-13 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 49.20× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.37B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.10 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 4 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.49% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-31.revenue_actual.comparison | Latest report · revenue vs estimate | In line | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($5.36B) with the recorded estimate ($5.36B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-31.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.9900) with the recorded estimate ($0.9470) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 88 of 100 · Exceptional · pillars 98 / 68 / 31 / 63 / 69 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.valuation_driver | Recorded valuation score driver | Price relative to book value is the main valuation drag relative to sector peers. | OURS | Stock Expert AI MoonshotScore v2 engine · stored factor contributions | |
ours.moonshot_change | MoonshotScore movement | 88 (stored snapshot Oct 4, 2026) → 88 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-07-31. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-31.revenue_actual,earn.history.depth.2026-07-31.revenue_estimated,earn.history.depth.2026-07-31.revenue_actual.comparison,earn.history.depth.2026-07-31.eps_actual.comparison,earn.history.depth.2026-07-31.eps_actual,earn.history.depth.2026-07-31.eps_estimated,earn.history.depth.2026-05-01.revenue_actual,earn.history.depth.2026-05-01.revenue_estimated,earn.history.depth.2026-05-01.eps_actual,earn.history.depth.2026-05-01.eps_estimated,earn.history.depth.2026-01-30.revenue_actual,earn.history.depth.2026-01-30.revenue_estimated,earn.history.depth.2026-01-30.eps_actual,earn.history.depth.2026-01-30.eps_estimated,earn.history.depth.2025-10-31.revenue_actual,earn.history.depth.2025-10-31.revenue_estimated,earn.history.depth.2025-10-31.eps_actual,earn.history.depth.2025-10-31.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners). These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare. Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand. Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Pet Nutrition: $4.61B; Oral, Personal and Home Care: $15.77B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-31 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Sector / industry (provider taxonomy) | Consumer Defensive / Household & Personal Products The company's SEC filings classify it under SIC 2844 — Perfumes, Cosmetics & Other Toilet Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Named officers | CEO: Noel R. Wallace; Officers: Chandrasekar — Title: Senior Vice President of Customer Development of Asia Pacific; Ram Raghavan — Title: Chief Marketing Officer, Born: 1973; Brigitte H. King — Title: Chief Digital & Insights Officer, Born: 1970; Carlos Campos — Title: Senior Vice President of Finance Andina; Elena Laskow — Title: Senior Vice President of Global Benefits; John Faucher — Title: Chief Investor Relations Officer and Executive Vice President of M&A; Warren Pruitt — Title: Senior Vice President of Global Engineering; Jolle Kirpensteijn — Title: Chief Veterinary Officer of Hill's Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-31 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-31 | OFFICIAL | SEC EDGAR filer submissions | |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $7.86B; Liquidity basis: cash and short-term investments; Total liabilities: $16.22B; Cash and short-term investments: $1.37B; Cash and investments: $1.37B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.37B; Cash and short-term investments: $1.37B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $1.37B; Decline: $124.00M; Opening balance: $1.49B; Average change per period: $17.70M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$6.49B; Total debt: $7.86B; Cash and investments: $1.37B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 0.67; Current ratio: 1.03; Debt to equity: 33.29; Net margin: 9.7%; Gross margin: 60.4%; Operating margin: 20.7%; Return on assets: 12.1%; Return on equity: 631.1% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 6.72; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-30; EPS estimate: $0.92 per share; Revenue estimate: $5.34B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-07-31 | OFFICIAL | SEC EDGAR filer submissions |
Data provided for informational purposes only.
ETFs that hold CL
Funds in our ETF coverage that list CL among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| FSTA ETF | 2.38% | |
| ProShares - Russell U.S. Dividend Growers ETF (TMDV) | 1.77% | |
| ProShares - S&P 500 Dividend Aristocrats ETF (NOBL) | 1.62% |